Mamontova, EM, Zakharenko, AL, Zakharova, OD, Dyrkheeva, NS, Volcho, KP, Reynisson, J ORCID: https://orcid.org/0000-0003-4174-9512, Arabshahi, HJ, Salakhutdinov, NF and Lavrik, OI (2019) Identification of novel inhibitors for the tyrosyl-DNA-phosphodiesterase 1 (Tdp1) mutant SCAN1 using virtual screening. Bioorganic & Medicinal Chemistry, 28 (1). 115234 - ?.

[img] Text
SCAN1-Manuscript.docx - Accepted Version
Restricted to Repository staff only until 30 November 2020.
Available under License Creative Commons Attribution Non-commercial No Derivatives.

Download (3MB)

Abstract

Spinocerebellar ataxia syndrome with axonal neuropathy (SCAN1) is a debilitating neurological disease that is caused by the mutation the Tyrosyl-DNA phosphodiesterase 1 (TDP1) DNA repair enzyme. The crucial His493 in TDP1's binding site is replaced with an arginine amino acid residue rendering the enzyme dysfunctional. A virtual screen was performed against the homology model of SCAN1 and seventeen compounds were identified and tested in a novel SCAN1 specific biochemical assay. Six compounds showed activity with IC50 values between 3.5 and 25.1 µM. The most active ligand 5 (3.5 µM) is a dicoumarin followed by a close structural analogue 6 at 6.0 µM. A less potent series of β-carbolines (14 and 15) was found with potency in the mid-teens. According to molecular modelling an excellent fit for the active ligands into the binding pocket is predicted. To the best of our knowledge, data on inhibitors of the mutant form of TDP1 has not been reported previously. The virtual hits were also tested for wild type TDP1 activity and all six SCAN1 inhibitors are potent for the former, e.g., ligand 5 has a measured IC50 at 99 nM. In the last decade, TDP1 is considered as a promising target for adjuvant therapy against cancer in combination with Topoisomerase 1 poisons. The active ligands are mostly non-toxic to cancer cell lines A-549, T98G and MCF-7 as well as the immortalized WI-38 human fetal lung cells. Furthermore, ligands 5 and 7, show promising synergy in conjunction with topotecan, a clinically used topoisomerase 1 anticancer drug. The active ligands 5, 7, 14 and 15 have a good balance of the physicochemical properties required for oral bioavailability making the excellent candidates for further development.

Item Type: Article
Additional Information: The final accepted version of this article can be found at; https://www.sciencedirect.com/science/article/pii/S0968089619312143?via%3Dihub#!
Uncontrolled Keywords: novel inhibitors, tyrosyl-DNA-phosphodiesterase 1, mutant, SCAN1
Subjects: Q Science > Q Science (General)
Q Science > QD Chemistry
R Medicine > R Medicine (General)
R Medicine > R Medicine (General) > R735 Medical education. Medical schools. Research
Divisions: Faculty of Medicine and Health Sciences > School of Pharmacy and Bioengineering
Related URLs:
Depositing User: Symplectic
Date Deposited: 17 Jan 2020 11:37
Last Modified: 17 Jan 2020 11:37
URI: https://eprints.keele.ac.uk/id/eprint/7518

Actions (login required)

View Item View Item